Increasingly, the public and private worlds are converging.
Month: August 2020
Luminar to enter limelight through reverse merger
Volvo Cars, Corning and Cornes-backed lidar technology developer Luminar is merging with a special purpose acquisition vehicle to form a company with an expected $3.4bn valuation.
Snowflake steers itself towards IPO
The Capital One and Salesforce-backed data management platform developer – valued at $12.4bn in February – has filed to go public.
American Family Ventures achieves $213m fund
The insurance firm’s corporate venturing unit has admitted external limited partners for its AFV Fund III, which just closed at $213m.
JFrog prepares to leap to public markets
The Dell-backed software management technology provider was valued at $1.5bn as of October and has initially filed to raise $100m.
SDIC slips $116m to Xuanzhu
China’s State Development and Investment Corporation has picked up an 18.6% stake in Sihuan Pharmaceutical’s drug development spinoff, Xuanzhu Biopharmaceutical.
Connect Biopharma links to $115m
Lilly Asia Ventures was among the new investors in a series C round for autoimmune and inflammatory disease drug developer Connect Biopharma.
Outset Medical touts IPO intentions
Baxter Ventures is set to exit the kidney dialysis device maker, which has just filed to go public following upwards of $430m in venture funding.
FarEye fattens up series D round
The predictive logistics platform developer has raised a further $13m, adding to $24.5m raised from investors including M12 and Honeywell Ventures in April.
Yidu Tech speeds toward public markets
The medical data software producer has filed to float in Hong Kong after raising nearly $340m from investors including Tencent and Sunshine Insurance.
Consolidating the market
Another one goes.
Nano-X nabs $165m in initial public offering
The SK Telecom, iA Financial, Foxconn and Fujifilm-backed X-ray technology developer priced the offering at the top of its range.
Kymera climbs to $174m IPO
The protein degradation drug developer’s valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.
Dataiku documents $100m series D round
CapitalG, which joined Dataiku’s shareholders through a secondary transaction last year, has now made its first primary investment in the data management software provider.